MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
According to MediWound Ltd.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -13.65. At the end of 2022 the company had a P/E ratio of -3.43.
Year | P/E ratio |
---|---|
2023 | -13.65 |
2022 | -3.43 |
2021 | -4.74 |
2020 | -10.49 |
2019 | 22.66 |
2018 | -104.14 |
2017 | -4.79 |
2016 | -5.30 |
2015 | -8.38 |
2014 | -7.01 |
2013 | -22.89 |
2012 | 32.13 |
2011 | -56.97 |